The DEA vs. FDA: Which Agency Regulates What in Compounded Medications

When patients hear about regulatory actions against compounding pharmacies, the stories often mention the FDA, state boards of pharmacy, and occasionally the DEA — sometimes in the same sentence. These agencies have different authorities, different mandates, and different enforcement approaches. Knowing which agency does what helps you understand the regulatory environment surrounding your compounded GLP-1 prescription.

The FDA's Role

The Food and Drug Administration regulates the safety, efficacy, and manufacturing quality of drugs — including compounded drugs. For compounding pharmacies, the FDA's authority covers:

• Manufacturing standards: The FDA enforces current Good Manufacturing Practice (cGMP) standards for outsourcing facilities (503B) and can take enforcement action against 503A pharmacies for conditions that present serious safety risks.
• Drug shortage list: The FDA maintains the drug shortage database that determines when compounding from bulk API is permissible for 503B outsourcing facilities.
• Bulks List: The FDA determines which bulk drug substances can be used by outsourcing facilities through the 503B Bulks List rulemaking process.
• Warning letters and enforcement: The FDA issues warning letters, consent decrees, and injunctions against pharmacies that violate federal compounding law — including those that compound drugs that are "essentially copies" of commercially available products, market compounded drugs with unsubstantiated claims, or operate with manufacturing deficiencies that endanger patient safety.
• Import controls: The FDA regulates the importation of active pharmaceutical ingredients (API), including blocking shipments of API from unregistered manufacturers.

The DEA's Role

The Drug Enforcement Administration regulates controlled substances — drugs with potential for abuse or dependence that are classified under the Controlled Substances Act. The DEA's relevance to compounding is more limited but still significant:

• Controlled substance registration: Pharmacies that handle controlled substances (Schedule II-V drugs) must register with the DEA and maintain specific recordkeeping and security requirements.
• Ordering and inventory: The DEA controls the procurement chain for controlled substances through the DEA Form 222 system and the Automation of Reports and Consolidated Orders System (ARCOS).
• Diversion prevention: The DEA investigates and enforces against unauthorized distribution, theft, or diversion of controlled substances from pharmacy settings.

Are GLP-1s Controlled Substances?

No. Semaglutide, tirzepatide, and liraglutide are not scheduled under the Controlled Substances Act. They have no abuse potential and are not classified as controlled substances by the DEA. This means the DEA has no direct regulatory authority over GLP-1 compounding specifically.

However, if a compounding pharmacy also handles controlled substances (as many do — compounding pharmacies may prepare controlled substance formulations like pain management or hormone preparations), the DEA's oversight of those activities can indirectly affect the pharmacy's operations. A DEA investigation into controlled substance handling at a pharmacy can lead to broader scrutiny of all the pharmacy's practices.

State Boards of Pharmacy

While not a federal agency, state boards of pharmacy are the primary day-to-day regulators of compounding pharmacies. Their authority includes:

• Licensure: Granting, renewing, suspending, or revoking pharmacy licenses.
• Inspections: Conducting routine and for-cause inspections of pharmacy facilities, personnel, and records.
• Standards enforcement: Enforcing USP <797>, <795>, and state-specific compounding regulations.
• Disciplinary action: Fining, restricting, or closing pharmacies that violate state pharmacy law.

For patients, the state board of pharmacy is often the most accessible regulatory body. License verification databases, inspection records, and complaint filing are typically available through the state board's website.

Where Authorities Overlap

The FDA and state boards occasionally have overlapping jurisdiction, particularly regarding manufacturing practices and safety standards. The FDA generally defers to state boards for routine compounding oversight but steps in when it identifies national safety concerns, when pharmacies distribute across state lines at scale, or when 503B outsourcing facilities are involved (which are federally registered and therefore primarily FDA-regulated).

This overlap can create enforcement gaps — a pharmacy may comply with its state board's standards but fall short of the FDA's expectations, or vice versa. The practical effect for patients is that state-level compliance does not guarantee federal-level compliance, and a pharmacy with a clean state record may still face FDA enforcement action.

Providers Operating Under Full Regulatory Compliance